People: Sanofi SA (SNY)

SNY on New York Consolidated

56.07USD
1 Oct 2014
Price Change (% chg)

$-0.36 (-0.64%)
Prev Close
$56.43
Open
$56.39
Day's High
$56.39
Day's Low
$55.99
Volume
256,619
Avg. Vol
1,064,332
52-wk High
$57.42
52-wk Low
$47.06

Search Stocks

Summary

Name Age Since Current Position

Serge Weinberg

62 2010 Chairman of the Board

Christopher Viehbacher

54 2008 Chief Executive Officer, Chairman of the Executive Committee and Global Leadership Team and Director

Jerome Contamine

56 2009 Executive Vice President - Chief Financial Officer, Member of the Executive Committee and Global Leadership Team

Peter Guenter

2013 Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team

David Meeker

2013 Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team

Pascale Witz

2013 Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team

Carsten Hellmann

49 2013 Executive Vice President - Animal Health and Member of the Global Leadership Team

Karen Linehan

55 2012 Member of the Executive Board, Member of the Management Board, Senior Vice President, General Counsel

Roberto Pucci

50 2009 Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team

Olivier Charmeil

51 2011 Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team

Philippe Luscan

51 2008 Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team

Jose Barella

2011 Senior Vice President - Animal Health and Member of the Global Leadership Team

David Loew

2013 Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe

Debasish Roychowdhury

2009 Senior Vice President - Global Oncology and Member of the Global Leadership Team

Paul Chew

2013 Senior Vice President, Chief Medical Officer and Head of Global Medical Affairs and Member of the Global Leadership Team

Dante Beccaria

2012 Vice President, Global Compliance Officer and Member of the Global Leadership Team

Sebastien Martel

2008 Vice President - Investor Relations and Member of the Global Leadership Team

Elias Zerhouni

62 2011 President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team

David-Alexandre Gros

41 2011 Chief Strategy Officer, Member of the Executive Committee and the Global Leadership Team

Thierry Desmarest

68 2000 Director

Igor Landau

69 2004 Director

Fabienne Lecorvaisier

52 2013 Director

Christian Mulliez

53 2004 Director

Uwe Bicker

68 2008 Independent Director

Robert Castaigne

67 2012 Independent Director

Lord Douro

68 2002 Independent Director

Jean-Rene Fourtou

75 2004 Independent Director

Claudie Haignere

56 2008 Independent Director

Suet Fern Lee

55 2011 Independent Director

Carole Piwnica

56 2010 Independent Director

Klaus Pohle

76 2004 Independent Director

Gerard Van Kemmel

74 2003 Independent Director

Biographies

Name Description

Serge Weinberg

Mr. Serge Weinberg has been Chairman of the Board at Sanofi SA since May 17, 2010. He is also Chairman of the Company's Nominating and Governance Committee as well as of Strategy Committee. Additionally, Mr. Weinberg is also Director of VL Holding, Manager of Alret and Maremma, and Member of the Supervisory Board of Schneider Electric and Financiere BFSA, among others. Previously, he was Director of Sanofi SA from December 16, 2009 until May 17, 2010. He became Chief of Staff of the French Budget Minister, Laurent Fabius, in 1981. After a position of Deputy General Manager for Finance at the French Television Channel FR3 (1982-1983), he became Chief Executive Officer and then Chairman of the Havas Tourisme Group, the function he held from 1983 to 1987. He was then appointed CEO of Pallas Finance for three years and joined the Pinault Group in 1990 as President of CFAO. In the Pinault Group, he was then appointed Chairman and CEO of Rexel for the period from 1991 to 1995 and chaired the Management Board of the PPR Group for 10 years. In March 2005, he founded the investment firm Weinberg Capital Partners, which manages funds dedicated to LBO and real estate. Mr. Weinberg was also Non-Executive Chairman of the Board of the Accor Group from 2006 to 2009. Mr. Weinberg obtained a degree in Law, a degree from the Institut d'Etudes Politiques de Paris and obtained a degree from the ENA - Ecole Nationale d'Administration Publique in 1976.

Christopher Viehbacher

Mr. Christopher A. Viehbacher has been Chief Executive Officer, Chairman of the Executive Committee and Global Leadership Team and Director of Sanofi SA as of December 1, 2008. He is also Member of the Company's Strategy Committee and has been President of Genzyme as of April 2011. In addition to that, he has been Chair of the CEO Roundtable on Cancer since February 2011. He also holds other mandates, including Vice Chairman of EFPIA (Belgium) and Member of the International Business Council, World Economic Forum (Switzerland), among others. From December 2010 to 2012, Mr. Viehbacher was Chairman of PhRMA in the United States. After starting his career at PriceWaterhouseCoopers, he spent the major part of his professional life (1988-2008) in the Wellcome group, GlaxoWellcome and then GlaxoSmithKline (GSK) where he held different positions across Europe (Germany, France, and Great Britain) and in the United States and Canada. In its last position, Mr. Viehbacher was President, Pharmaceutical Operations North America, Co-Chairman of the Portfolio Management Board. He was made a knight of the French Legion of Honor in 2003. Mr. Viehbacher obtained a Bachelor of Arts degree in Commerce from the Queens University of Ottawa (Canada) and is a Certified Public Accountant.

Jerome Contamine

Mr. Jerome Contamine has served as Executive Vice President - Chief Financial Officer, Member of the Executive Committee and Global Leadership Team of Sanofi SA as of March 16, 2009. After four years at the Cour des Comptes as a Senior State General Auditor, he joined Elf Aquitaine in 1988, as Advisor to the Chief Financial Officer, and became Group Finance Director & Treasurer in 1991. He became General Manager of Elf Petroleum Norway in 1995, after being named Deputy Vice President of Elf Upstream Division for Europe and the U.S. In 1999, he was appointed Member of the taskforce for integration with Total, in charge of the reorganization of the merged entity, TotalFinaElf, and became, in 2000, Vice President Europe and Central Asia, Upstream Division of Total. The same year, he joined Vivendi Environnement as CFO and Deputy General Manager. In 2003, he became Senior Executive Vice President, Deputy General Manager, Chief Financial Officer of Veolia Environnement and Director of Valeo. Mr. Contamine obtained a degree from the Ecole Polytechnique in 1979 and from the Ecole Nationale de la Statistique et de l'Administration de l'Economie (ENSAE). He also earned a degree from the Ecole Nationale d'Administration in 1984.

Peter Guenter

Mr. Peter Guenter is Executive Vice President in charge of Global Commercial Operations and a Member of the Executive Committee and the Global Leadership Team of Sanofi SA as of July 1, 2013. He holds a Masters Degree in Physical Education at the Faculty of Medicine and Health Sciences, University of Ghent, Belgium. He started his career in Sales at SmithKline in 1986. He joined the Group in 1995 and held various positions in France, Europe and Global Marketing. In 2000, he was appointed General Manager Belgium and then Vice President for Eastern Europe, Northern Europe & Scandinavia. In 2008, he was appointed General Manager, Commercial Operations for Germany, and in 2011, he was General Manager for the Multi-Country- Organisation for Germany, Switzerland and Austria.

David Meeker

Dr. David P. Meeker, M.D. has been Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team of Sanofi SA since September 1, 2013. He has been Chief Executive Officer of Genzyme since 2010 and served as Chief Executive Officer of Genzyme and Member of the Global Leadership Team of the Company from November 1, 2011 to September 1, 2013. He joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. In 1998, he was appointed Senior Vice President, Medical Affairs, before taking up the role of Senior Vice President for Therapeutics Europe. In 2003, he was appointed President of LSD Therapeutics, where he oversaw the global launches of Aldurazyme, Fabrazyme and Myozyme. He was promoted to Executive Vice President of therapeutics, biosurgery and corporate operations in 2008. Prior to joining Genzyme, he was Director of the pulmonary critical care fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He received his M.D. (a Doctorate of Medicine) degree from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000.

Pascale Witz

Ms. Pascale Witz is Executive Vice President in charge of Global Divisions & Strategic Commercial Development, and a Member of the Executive Committee and the Global Leadership Team of Sanofi SA, effective as of July 1, 2013. She has been President & Chief Executive Officer of Medical Diagnostics at GE Healthcare since 2009. She started her career in a research lab before moving to marketing at Becton Dickinson France in 1991. She joined GE Healthcare in 1996 as Product Manager for the vascular business in France. Over the years, she also worked within GE in Europe, Africa, Middle East and the United States. Prior to taking up the position of President & CEO of the medical diagnostics business, she was VP & General Manager for the Global Interventional Business for France and United States (2008-2009). Throughout her career within GEHC, Ms. Witz headed up a number of businesses. She was General Manager, Computed Tomography (2006-2007), VP Sales & Marketing Services (2005-2006), General Manager, Nuclear Medicine & PET (2002-2004), VP Information Technology and VP Six Sigma and Quality (2000-2001). She holds a Master's degree in life sciences/molecular biology from Institut National des Sciences Appliquees Lyon and an MBA from INSEAD.

Carsten Hellmann

Mr. Carsten Hellmann has been Executive Vice President - Animal Health and Member of the Global Leadership Team at Sanofi SA as from September 1, 2013. In his previous role, he was Executive Vice President, Global Sales, Chr. Hansen Holding A/S, a position he took upon joining the company in 2006. He obtained a Master of Science degree in Information Management from the Lancaster University and a Bachelor of Science degree in Business Administration from Copenhagen Business School.

Karen Linehan

Ms. Karen Linehan has been Member of the Executive Board, Member of the Management Board, Senior Vice President, General Counsel of Sanofi SA since April 1, 2012. Previously, she served as Senior Vice President - Legal Affairs and General Counsel, Global Compliance Officer Interim, Member of the Executive Committee and the Global Leadership Team of the Company from 2011 to April 1, 2012. Between March 26, 2007 and 2011, she held the functions of Senior Vice President - Legal Affairs and General Counsel, Member of the Executive Committee and Management Committee of Sanofi SA. Prior to practicing law, Ms. Linehan served on the congressional staff of the Speaker of the U.S. House of Representatives from September 1977 to August 1986. Until December 1990, she was Associate in a law firm in New York, New York. In January 1991, she joined Sanofi as Assistant General Counsel of its US subsidiary. In July 1996, Ms. Linehan moved to Paris to work on international matters within the Group and she has held a number of positions within the Legal Department, most recently as Vice President - Deputy Head of Legal Operations. Ms. Linehan obtained a Bachelor of Arts degree in Literature and a Juris Doctor degree in Law, both from the Georgetown University.

Roberto Pucci

Mr. Roberto Pucci has been Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team at Sanofi SA as of October 2009. He has a degree in Law from the Universite de Lausanne, Switzerland. He started his career in 1985 at Coopers & Lybrand in Geneva, Switzerland as an external auditor. He then joined Hewlett- Packard (HP) in 1987, where he held various positions in Human Resources in Switzerland and Italy including Human Resources Manager for the European Headquarter and Human Resources Director in Italy. In 1999, he became Director, Compensation and Benefits for Agilent Technologies, a spin off from HP, and was appointed Vice President Human Resources Europe in 2003. In 2005 he moved to the United States to join Case New Holland, a subsidiary of the Fiat Group, as Senior Vice President, Human Resources, and was appointed, in 2007, Executive Vice President, Human Resources for the Fiat Group in Torino, Italy.

Olivier Charmeil

Mr. Olivier Charmeil has been Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team of Sanofi SA since January 1, 2011. He joined the Company as Senior Vice President - Pharmaceutical Operations in Asia-Pacific Region on February 1, 2006, the function he held until January 1, 2008, when he became appointed Senior Vice President - Pharmaceutical Operations in Asia Pacific Region and Japan for over one year, until February 2009. From then to January 1, 2011, he served as Senior Vice President - Asia/Pacific & Japan Vaccines, Member of the Management Committee of the Company. From 1989 to 1994, he worked in the Mergers and Acquisitions department of Banque de l’Union Europeenne. He joined Sanofi Pharma in 1994 as Head of Business Development. Subsequently, he held various posts within the Group, including Chief Financial Officer (Asia) for Sanofi-Synthelabo in 1999 and Attache to the Chairman, Jean-Francois Dehecq, in 2000, before being appointed as Vice President of Development within the Sanofi-Synthelabo International Operations Division, where he was responsible for China and support functions. In 2003, Mr. Charmeil was appointed Chairman and Chief Executive Officer of Sanofi-Synthelabo France, before taking the post of Senior Vice President of Business Management and Support within the Pharmaceutical Operations Division. Mr. Charmeil obtained a degree from the Hautes etudes commerciales (HEC) and from the Institut d'Etudes Politiques de Paris.

Philippe Luscan

Mr. Philippe Luscan has been Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team of Sanofi SA since September 2008. He previously served as Vice President - Chemistry of the Company from September 2006 to September 2008. He graduated from Ecole Polytechnique and from Ecole des Mines de Paris in Biotechnology. He started his career with Danone in 1987 as Head of Production. He joined the Company in 1990, as Plant Director for Sanofi Chimie in Sisteron. He then became Industrial Director for Sanofi in the United Sates, followed by an appointment as Vice President of Supply Chain.

Jose Barella

Mr. Jose Barella has been Senior Vice President - Animal Health and Member of the Global Leadership Team of Sanofi SA since 2011. He holds a degree in Chemical Engineering from Escola de Engenharia Maua, Sao Paulo Brazil, and began his career in Chemical Engineering field with management positions with Alcoa and Cosipa Steel in Brazil. Before joining Merial in 2001 as Head of Companion Animals Global Enterprise and Head of Merial's Supply Chain, he spent over 20 years in global agriculture and life sciences industries, with Aventis Environmental Science (AES), Rhone-Poulenc Agriculture, and Rhone-Poulenc Rorer. While at AES, he was responsible for all operational/strategic aspects non-agricultural business of Aventis CropScience, including strategy, R&D, marketing, manufacturing, supply chain, finance and HR. Mr. Barella became Merial's Chief Operating Officer and Head of Business Operations in 2005, where he oversaw all commercial activities of the entire Merial product line globally, including sales and marketing and supply chain for the Companion Animal, Production Animal, Avian, Swine and Veterinary Public Health businesses. He was appointed Executive Chairman of Merial Limited in 2007.

David Loew

Mr. David Loew was appointed as Member of the Global Leadership Team and Senior Vice President - Commercial Operations Europe at Sanofi SA effective on July 1, 2013. He is also Chairman of the Company's European Strategic Committee. He graduated from Universitaet St. Gallen with an MBA degree. Prior to joining the Company, Mr. Loew worked at Roche Pharmaceuticals as Regional Head Eastern Europe, Middle East and Africa. He started his career with traineeships in the US at Coopers & Lybrand and Hewlett Packard in 1990, before joining Roche in 1992 as a sales representative in Vienna, Austria. He moved to Basel in 1993 for a management development programme and then took up the position of Senior Product Manager in France in 1995. Within two years, he was promoted to Marketing Manager for transplantation and dialysis. In 1999, he was appointed Business Director, Specialty Care in Mexico. Mr. Loew was promoted in 2001 to global marketing roles of Life Cycle Leader, splitting his time between Nutley, New Jersey and Basel, Switzerland. He subsequently took over the position as Oncology Head. After six years in marketing roles, he became General Manager Switzerland in 2007 and at the beginning of 2010, was appointed Global Chief Marketing Officer / Head of Global Product Strategy for the pharmaceuticals division of Roche.

Debasish Roychowdhury

Mr. Debasish Roychowdhury served as Senior Vice President - Global Oncology and Member of the Global Leadership Team of Sanofi SA. He received his medical training and a Doctorate of Medicine degree from the All India Institute of Medical Sciences (AIIMS), New Delhi, and then moved to the United States in 1989 to specialize in internal medicine, hematology and oncology (at the University of California at San Francisco), and subsequently taught at the Faculty of Mecinine of the University of Cincinnati, where he directed a number of clinical programs. In 1999, he moved to Eli-Lilly's R&D Department to work in Oncology Clinical Research and later in Regulatory Affairs, and was appointed Vice President for Clinical Development at GlaxoSmithKline in 2005. In 2008, he was part of the team that created GSK's new Oncology R&D Unit, uniting all of the teams working on the subject.

Paul Chew

Dr. Paul Chew has been Senior Vice President, Chief Medical Officer and Head of Global Medical Affairs and Member of the Global Leadership Team of Sanofi SA as of January 1, 2013. Dr. Chew was appointed Senior Vice President - Chief Medical Officer/Chief Scientific Officer US and Member of the Global Leadership Team of the Company in January 2009. Between 2007 and 2009, Dr. Chew held the position of President, US Research & Development and Vice President, Therapeutic Department Head, Metabolism, Diabetes and Thrombosis, responsible for Lovenox, Lantus, and the therapeutic development portfolio. Between 2001 and 2004, Dr. Chew was Vice-President, Global Head of Metabolism and Diabetes at Aventis Pharmaceuticals. He held numerous positions at Bristol-Myers Squibb between 1992 & 2001, including Vice President, US Medical Affairs (1999-2001). Prior to joining the industry, Dr. Chew was Assistant Professor of Medicine at The Johns Hopkins Hospital, Attending Physician in Radiology, Director of the Pacemaker Clinic and Member of the Interventional Cardiology staff.

Dante Beccaria

Mr. Dante Beccaria has been Vice President, Global Compliance Officer and Member of the Global Leadership Team at Sanofi SA since April 1, 2012. He holds a Degree in Economics from the University of Pavia (Italy). He began his career in 1985 in the field of Financing & Treasury and bank relationships first at Shell Italy and then Alcatel Italy. Mr. Beccaria has over 20 years' experience within Sanofi, having covered both operational and Corporate responsibilities. In 1990, he joined the Sanofi Italian affiliate to implement a Treasury Platform, gathering all the Business activities in the country. In 1992, he was appointed Controlling Director of the Italian Pharma affiliate. In 1997, he moved to Paris to take global responsibilities as Pharma Controller at Sanofi Corporate, then as CFO of the OTC & Generics Division. In 2001, he became Projects Director within the Mergers & Acquisitions Corporate department. In 2003, he joined the Corporate Internal Audit as Associate Vice President. He was then appointed Vice President Internal Audit after the acquisition of Aventis.

Sebastien Martel

Mr. Sebastien Martel has been Vice President - Investor Relations and Member of the Global Leadership Team of Sanofi SA since September 1, 2008. He holds a Doctorate in Pharmacy, a Masters in Pharmaceutical Marketing Management, as well as an MBA from INSEAD or Institut Europeen d'Administration des Affaires, France. Previously, he was International Marketing Director at Novo Nordisk. Prior to Novo Nordisk, he was Vice President, Investor Relations at Serono. At Serono, he previously had global strategic marketing responsibility for the Reproductive Health portfolio. Before joining Serono, he was Marketing Director with Fournier in Canada, after holding several product management positions.

Elias Zerhouni

Dr. Elias Zerhouni, M.D., has served as President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team of Sanofi SA as of January 1, 2011. In February 2009, Sanofi named Dr. Zerhouni, M.D., Scientific Advisor to Chief Executive Officer and to Senior Vice-President Research & Development. He received his basic education and training in Algeria, and his academic career was spent at the Johns Hopkins University and Hospital where he is currently Professor of Radiology and Biomedical Engineering and Senior Adviser for Johns Hopkins Medicine. He served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research and Executive Vice Dean of the School of Medicine from 1996 to 2002 before his appointment as Director of the National Institutes of Health of the United States of America from 2002 to 2008. He has authored over 200 publications, holds eight patents and has founded or co-founded five start-up companies. Dr. Zerhouni, M.D., holds a number of positions on Boards, including most recently, Senior Fellow of the Bill and Melinda Gates Foundations, the board of trustees of the Mayo Clinic and the Lasker Foundation. He earned membership into the Institute of Medicine of the US National Academy of Sciences in 2000 and received the Legion of Honor medal from the French National Order in 2008. He was appointed as Chair of Innovation at the College de France and elected to membership at the French Academy of Medicine in 2010. He also received the Transatlantic Innovation Leadership award in December 2011.

David-Alexandre Gros

Mr. David-Alexandre Gros, M.D., has been Chief Strategy Officer, Member of the Executive Committee and the Global Leadership Team of Sanofi SA as of September 1, 2011. He worked in clinical and health outcomes research at the Department of Urology of the Johns Hopkins Hospital from 1996 to 1999, and then as Resident Physician at the University of Pennsylvania Health System from 1999 to 2000. In 2002, he joined McKinsey & Company's Pharmaceuticals & Medical Products practice as an Associate, and was promoted to Engagement Manager in 2004, and to Associate Principal in 2006. In late 2006, he joined Merrill Lynch as Vice President in Healthcare Investment Banking focusing on strategy, mergers & acquisitions and corporate finance until joining Centerview Partners in mid-2009 as Principal and Founding Member of the Healthcare Investment Banking Division. He obtained a Bachelor of Arts degree from the Dartmouth College in 1995, a Doctorate of Medicine from the Johns Hopkins University in 1999. He also received a Masters of Business Administration degree from the Harvard Business School in 2002.

Thierry Desmarest

Mr. Thierry Desmarest has been Director of Sanofi SA since February 21, 2000 and is also Member of the Company's Remuneration Committee, Nominating and Governance Committee and Strategy Committee. Additionally, he is also Honorary Chairman and Director, Chiarma of the Nomination and Governance Committee, as well as Member of the Remunerations and Strategic Committees of Total SA, Director of Air Liquide, Renault SA, Renault SAS, Bombardier Inc and Musee du Louvre, among others. Since 1981, Mr. Desmarest has held various positions at the Total group, including Chairman and Chief Executive Officer (1995-2007) and Chairman of the Board from February 14, 2007 until May 2010. Until 2010, he was also Member of the Supervisory Board of Areva. He graduated from the Ecole Polytechnique de Paris in 1966 and from the Ecole Narionale Superieurs des Mines de Paris (Ecole des Mines de Paris in 1970).

Igor Landau

Mr. Igor Landau has been Director of Sanofi SA as of August 2004. He is also Director of INSEAD, Member of the Supervisory Boards of Allianz AG and Chairman of the Supervisory Board of Adidas-Salomon. Until 2012, he was Director of HSBC France, among others. Mr. Landau previously served as Chief Executive Officer of the German subsidiary of La Compagnie du Roneo from 1968 to 1970, Management consultant at McKinsey in France from 1971 to 1975, and then held until 2004 various positions at the Rhone-Poulenc group, including member of the Management Board of Aventis (1999-2002) and Chairman of the Management Board of Aventis (2002-2004). Between 2001 and 2005, he was a Director of Essilor, and he also served as Director of Thomson (now called Technicolor) from 2002 to 2005 and as Member of the Supervisory Board of Dresdner Bank from 2003 to 2006.

Fabienne Lecorvaisier

Ms. Fabienne Lecorvaisier is Board Member of Sanofi SA. She began her career at Societe Generale and later held various positions at Barclays Bank and the Banque du Louvre. In 1993, she joined the Essilor Group as Development Director before being appointed Finance and Information Systems Director of Essilor America in 1996, then Chief Financial Officer of the Group in 2001 and Senior Vice-President Strategy and Acquisitions in 2007. In 2008, she was appointed Vice-President, Finance and Administration of the Air Liquide Group, and member of its Group Executive Committee. She is a graduate of Ecole Nationale des Ponts et Chaussees.

Christian Mulliez

Mr. Christian Mulliez has been Director of Sanofi SA since June 2004. He is also Member of the Audit and Remuneration Committees of the Company. Additionally, Mr. Mulliez serves as Chairman of the Board of Regefi, and Director of DG 17 Invest, L'Oreal USA Inc., Galderma Pharma and of The Body Shop International. He has been Executive Vice Chairman and General Manager Administration and Finance at L'Oreal since 2003. Between 1984 and 2002, he held various positions at Synthelabo and then at Sanofi-Synthelabo, including Vice President Finance. Mr. Mulliez is a graduate from the Ecole Superieure des Sciences Economiques et Commerciales (ESSEC).

Uwe Bicker

Mr. Uwe Bicker has been Independent Director of Sanofi SA since May 14, 2008. He is also Member of the Strategy Committee of the Company. Additionally, he serves as Member of the Supervisory Board of Foundation Aventis and of Future Capital AG, as well as Member of the Consulting Committee of Morgan Stanley. As of 2011, he has been the Dean at the Medical Faculty of the Heidelberg University, where he has been Professor since 1983, and he also became Managing Director at the University Clinic of Mannheim in 2011. He is also an Honorary Senator of Heidelberg University and an Honorary Doctor of the Klausenburg University. During his professional career, Mr. Bicker was also appointed as Trustee of Fondation Aventis. Between 1975 and 1994, he held various positions at Boehringer Mannheim GmbH (later Roche AG) and from 1994 to 2004, he held various positions at Hoechst group. Until 2012, Mr. Bicker also served as Chairman of the Supervisory Board of Siemens Healthcare Diagnostics Holding GmbH, Vice Chairman of the Supervisory Board of Epigenomics AG and of Definiens AG. He is a Physician and holds a Doctorate in Chemistry and Medicine.

Robert Castaigne

Mr. Robert Castaigne has been Independent Director of Sanofi SA since May 4, 2012. He is also Member of the Audit Committee of the Company. Additionally, Mr. Castaigne serves as Director of Vinci and Societe Generale. He is also Member of the Audit, Internal Control and Risks Committee of Societe Generale, as well as Member of the Audit and Remuneration Committees of Vinci. Previously, he served as Director of Sanofi SA from February 21, 2000 to May 4, 2012. Until 2011, he held the posts of Director and Member of the Audit Committee of Compagnie Nationale a Portefeuille, among others. Between 1972 and 2008, he held various positions at the Total group, including Chief Financial Officer and Member of the Executive Committee (June 1994 to May 2008). He was also Chairman and Chief Executive Officer of Total Chimie (1996-2008) and of Total Nucleaire (1992-2008), amongst other positions. Mr. Castaigne holds a degree from the Ecole Centrale de Lille and the Ecole Nationale Superieure du Petrole et des Moteurs, and also holds a Doctorate in Economics from the Universite Paris I Pantheon Sorbonne.

Lord Douro

Mr. Lord Douro has been Independent Director of Sanofi SA since May 22, 2002. He is also Member of the Company's Nominating, Governance and Strategy Committees. Additionally, he acts as Chairman of Richemont Holdings UK Ltd and Kings College London, Director of Compagnie Financiere Richemont AG, GAM Worldwide and RIT Capital, as well as Member of the Nominating and Remunerations Committees of Compagnie Financiere Richemont AG, among others. Previously, Mr. Douro was Director and Member of the Remuneration and Nominating Committee of Pernod Ricard, as well as Director of Abengoa Bioenergy until 2011, among others. From 1979 to 1989, he served as Member of the European Parliament, from 1995 to 2000, as Chairman of Sun Life & Provincial Holdings Plc and from 1993 to 2005, as Chairman of Framlington Group Ltd (United Kingdom). Mr. Douro holds a Master of Arts degree from the University of Oxford.

Jean-Rene Fourtou

Mr. Jean-Rene Fourtou has been Independent Director of Sanofi SA since August 2004 and he is also Member of the Remuneration, Nominating and Governance Committees and of the Strategy Committee of the Company. He is also Chairman of the Supervisory Board of Vivendi and Member of the Supervisory Board of Maroc Telecom. He served as Director and Member of the Remunerations Committee of Nestle until 2012. Until 2010, he served as Director of NBC Universal Inc, among others. Mr. Fourtou previously held various positions at the Bossard group from 1963 to 1986, including Chairman and Chief Executive Officer (1977-1986). From 1986 to 1999, he was Chairman and Chief Executive Officer of Rhone-Poulenc; between 1999 and 2004, he was Vice Chairman of the Management Board, Vice Chairman of the Supervisory Board and Member of the Strategy Committee of Aventis; and from 2002 to 2005, he was Chairman and Chief Executive Officer of Vivendi. He also held various mandates, including Vice President then Member of the Supervisory Board of Axa from 1990 to 2009. Mr. Fourtou graduated from the Ecole Polytechnique de Paris in 1963.

Claudie Haignere

Ms. Claudie Haignere has been Independent Director of Sanofi SA since May 14, 2008. She is also Member of the Company's Nominating, Governance and Remuneration Committees. She is Chairman of the Board of La Geode and Chairman of Universcience (Cite des Sciences et de l'Industrie and Palais de la Decouverte), and holds various other mandates, including Director of France Telecom, Fondation de France, Fondation CGenial, Fondation d'Entreprise L'Oreal and Fondation Lacoste, among others. Ms. Haignere is a Certified Rheumatologist and holds a Doctorate in Science specialized in Neurosciences. She was selected in 1985 by CNES (French National Space Center) as a candidate astronaut. She worked as a Rheumatologist, Cochin Hospital (Paris), from 1984 to 1992, and took part in the Scientific space mission to the MIR space station (Cassiopee Franco-Russian mission) in 1996, and in the Technical and scientific space mission to the International Space Station (Andromede mission) in 2001. Between 2002 and 2004, she was the Deputy Minister for Research and New Technologies in the French government, and from 2004 to 2005, she served as Deputy Minister for European Affairs. Until 2011, she was Vice Chairman of IAA and Director of Aero Club de France, among others.

Suet Fern Lee

Ms. Suet Fern Lee has been Independent Director of Sanofi SA as of May 6, 2011. She has been Senior Partner of Stamford Law Corporation, Singapore since 2000. She also became President-Elect of the Inter-Pacific Bar Association (IPBA) in 2008. Since 2006, she has been Member of the Board of trustees of Nanyang Technological University, Member of the Accountant Advisory Board of the National University of Singapore Business School since 2006, as well as Member of the Advisory Committee of the Singapore Management University School of Law since 2007. Ms. Lee is also Chairman of the Board of the Asian Civilisations Museum, which is one of the National Museums of Singapore, and Director of the following companies: Axa, Macquarie International Infrastructure Fund Ltd, National Heritage Board, Rickmers Trust Management Pte Ltd and Stamford Corporate Services Pte Ltd. Ms. Lee obtained a degree in Law from the Cambridge University in 1980 and she qualified as a Barrister-at-Law at Gray's Inn London in 1981 before qualifying to the Singapore bar in 1982.

Carole Piwnica

Ms. Carole Piwnica has been Independent Director at Sanofi SA since December 15, 2010 and she has bee also Member of the Company's Audit Committee since December 13, 2011. Additionally, she serves as Director of Naxos UK Ltd, Eutelsat, Louis Delhaize, Big Red (United States), Elevance (United States) and Amyris Inc. She is also Director and Chairman of the Governance Committee of Eutelsat Communications. Ms. Piwnica started her professional career in 1985 at Proskauer Rose, New York, before joining the merger & acquisitions department of Shearman & Sterling, Paris, in 1987. She was General Counsel at Gardini et Associes from 1991 to 1994 when she joined Amylum Group where she was appointed Chairman in 1996 having previously served as Chief Executive Officer of Amylum France. In 1996, she was appointed Vice-president and Board Member of Tate & Lyle Plc. She also served as Director of Spadel (Belgium) from 1998 to 2004, Director and Vice-Chairman for Governmental Affairs from 2000 to 2006, Chairman of the Liaison Committee and director of the CIAA (Confederation of the Food and Drink Industries of the European Union) from 1996 to 2006, and Chairman of the Export Commission and director of the Association Nationale des Industries Alimentaires from 2000 to 2006. Until 2011 she was Director of Aviva Plc, among others. Ms. Piwnica holds a Juris Doctor degree from the Universite Libre de Bruxelles and a Masters in Law (Master of Legal Letters) degree from the New York University, and was admitted to the Paris and New York Bars.

Klaus Pohle

Mr. Klaus Pohle has been Independent Director of Sanofi SA since August 2004 and is also Chairman of the Audit Committee of the Company. He also serves as Member of the Supervisory Board of Fondation Aventis. Mr. Pohle was Chairman of the German Accounting Standards Board (GASB) from 2003 to 2005, Deputy Chief Executive Officer and Chief Financial Officer of Schering AG from 1981 to 2003, and held various positions at the BASF group from 1966 to 1980. He holds a Doctorate (Doctorate in Philosophy) degree in Law from the Frankfurt University (Johann Wolfgang Goethe-Universitaet Frankfurt am Main), a Doctorate (Doctorate in Philosophy) degree in Economics from the University of Berlin, a Masters degree in Law from the Harvard University, and is a Professor of Business Administration at the Berlin Institute of Technology.

Gerard Van Kemmel

Mr. Gerard Van Kemmel has been Independent Director of Sanofi SA since May 19, 2003. He is also Chairman of the Remuneration Committee and Member of the Audit, and Nominating and Governance Committees of the Company. He is also Director and Member of the Audit Committee of Europacorp. Until 2010, he was Director of Eurotunnel NRS Holders Company Limited and of Eurotunnel Group. Between 2004 and 2006, he served as Chairman of Novell for Europe. From 2008 to 2010, he was Director of Groupe Europtunnel. Between 1966 and 1995, he held various positions, including President of Arthur Andersen and Andersen Consulting in France (1976-1995) and Chairman of the Board of Arthur Andersen Worldwide (1989-1994). From 1996 to 1997, he served as Senior Advisor to the French Finance Minister and then, between 1996 and 2006, he held various positions at Cambridge Technology Partners (Chief Operating Officer) and at Novell (President EMEA). Mr. Van Kemmel obtained a degree from the Ecole des Hautes Etudes Commerciales (HEC) and holds an MBA degree from the Stanford Business School.
Search Stocks